Similarly, CV9202, an RNActive®-based cancer immunotherapy that encodes survivin and other tumor-associated antigens—New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, trophoblast glycoprotein, and Mucin-1. Here, BIRC5 is linked to cancer.